Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 11/20 | 0.52 |
| ▸ | F11 | P03951 | 4/20 | 0.50 |
| ▸ | TPSB2 | P20231 | 4/20 | 0.50 |
| ▸ | PLAU | P00749 | 3/20 | 0.50 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.50 |
| ▸ | PLG | P00747 | 2/20 | 0.50 |
| ▸ | F7 | P08709 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23218745 | 1.00 | CFD (0.52) | CFDF11TPSB2PLAUKLKB1 | |
| SCHEMBL23218976 | 0.94 | CFD (0.51) | CFDF11TPSB2PLAUKLKB1 | |
| SCHEMBL29592685 | 0.94 | CFD (0.51) | CFDF11TPSB2PLAUKLKB1 | |
| SCHEMBL29852612 | 0.92 | CFD (0.54) | CFDF11TPSB2PLAUKLKB1 | |
| SCHEMBL23218324 | 0.92 | CFD (0.54) | CFDF11TPSB2PLAUKLKB1 | |
| SCHEMBL23218424 | 0.90 | CFD (0.53) | CFDF11TPSB2PLAUKLKB1 | |
| SCHEMBL29592676 | 0.90 | CFD (0.53) | CFDF11TPSB2PLAUKLKB1 | |
| SCHEMBL23218647 | 0.89 | FFAR1 (0.53) | CFDF11TPSB2PLAUKLKB1 | |
| SCHEMBL23218805 | 0.89 | CFD (0.52) | CFDF11TPSB2PLAUKLKB1 | |
| SCHEMBL29592616 | 0.89 | FFAR1 (0.53) | CFDF11TPSB2PLAUKLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4041238-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2022-08-17 | — | — | EP | disclosed |
| CN-114502168-A | Oral complement factor D inhibitors | 拜奥克里斯特制药公司 | 2022-05-13 | — | — | CN | disclosed |